158 related articles for article (PubMed ID: 26595259)
1. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction.
Shibata T; Ebata T; Fujita K; Shimokata T; Maeda O; Mitsuma A; Sasaki Y; Nagino M; Ando Y
Cancer Sci; 2016 Feb; 107(2):168-72. PubMed ID: 26595259
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Joerger M; Huitema AD; Koeberle D; Rosing H; Beijnen JH; Hitz F; Cerny T; Schellens JH; Gillessen S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):113-24. PubMed ID: 24166106
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older.
Yukisawa S; Ishii H; Matsuyama M; Kuraoka K; Takano K; Kamei A; Ozaka M
Jpn J Clin Oncol; 2011 Jan; 41(1):76-80. PubMed ID: 20926412
[TBL] [Abstract][Full Text] [Related]
5. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
Mané JM; Sancho A; Muñoz A; Rubio I; Fernández R; Carrera S; Fuente N; Ballesteros D; Casas R; Marrodán I; Mielgo X; López-Vivanco G
Tumori; 2010; 96(3):405-10. PubMed ID: 20845800
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).
Fujiwara Y; Kobayashi S; Nagano H; Kanai M; Hatano E; Toyoda M; Ajiki T; Takashima Y; Yoshimura K; Hamada A; Minami H; Ioka T
PLoS One; 2015; 10(12):e0143072. PubMed ID: 26633034
[TBL] [Abstract][Full Text] [Related]
8. Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
Zanon C; Alabiso O; Grosso M; Buosi R; Chiappino I; Clara R; Satolli A; Zai S; Bortolini M; Botta M; Mussa A
Int J Pancreatol; 2000 Jun; 27(3):225-33. PubMed ID: 10952405
[TBL] [Abstract][Full Text] [Related]
9. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
Kuemmerle A; Decosterd LA; Buclin T; Liénard D; Stupp R; Chassot PG; Mosimann F; Lejeune F
Cancer Chemother Pharmacol; 2009 Jan; 63(2):331-41. PubMed ID: 18587581
[TBL] [Abstract][Full Text] [Related]
10. A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia.
Kanai M; Morita S; Matsumoto S; Nishimura T; Hatano E; Yazumi S; Sasaki T; Yasuda H; Kitano T; Misawa A; Ishiguro H; Yanagihara K; Ikai I; Doi R; Fukushima M
Ann Oncol; 2009 Aug; 20(8):1397-401. PubMed ID: 19457938
[TBL] [Abstract][Full Text] [Related]
11. Toxicities of gemcitabine in patients with severe hepatic dysfunction.
Teusink AC; Hall PD
Ann Pharmacother; 2010 Apr; 44(4):750-4. PubMed ID: 20233917
[TBL] [Abstract][Full Text] [Related]
12. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Takamori H; Kanemitsu K; Tsuji T; Tanaka H; Chikamoto A; Nakahara O; Hiraoka T; Ikeda O; Kudo K; Imuta M; Yamashita Y
Pancreas; 2005 Apr; 30(3):223-6. PubMed ID: 15782098
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
18. The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer.
Goto K; Matsuyama R; Suwa Y; Arisaka S; Kadokura T; Sato M; Mori R; Kumamoto T; Taguri M; Endo I
Cancer Chemother Pharmacol; 2018 Dec; 82(6):953-960. PubMed ID: 30218151
[TBL] [Abstract][Full Text] [Related]
19. Review of gemcitabine in biliary tract carcinoma.
Scheithauer W
Semin Oncol; 2002 Dec; 29(6 Suppl 20):40-5. PubMed ID: 12577232
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
Sun W; Haller D
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):16-9. PubMed ID: 14569842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
